2-tert-butyl-5,6-dihydro-4H-cyclopentathiophene | 142396-94-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-tert-butyl-5,6-dihydro-4H-cyclopentathiophene
• 英文别名: 2-(t-butyl)-5,6-dihydro-4H-cyclopenta[b]thiophene；2-tert-butyl-5,6-dihydro-4H-cyclopenta[b]thiophene
• CAS: 142396-94-9
• 化学式: C₁₁H₁₆S
• 分子量: 180.314
• InChiKey: JRAFSJLHKAOKGS-UHFFFAOYSA-N

物化性质

• 沸点：
  227.0±9.0 °C(Predicted)
• 密度：
  1.032±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-叔丁基噻吩 在 正丁基锂 、 硼酸三甲酯 、 双氧水 、 sodium hydride 作用下， 以 二甲基亚砜 、 正戊烷 为溶剂， 反应 40.0h， 生成 2-tert-butyl-5,6-dihydro-4H-cyclopentathiophene
  参考文献：
  名称：

  Hinrichs, Heiko; Margaretha, Paul, Chemische Berichte, 1992, vol. 125, # 10, p. 2311 - 2318

  摘要：

  DOI：

文献信息

• CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：BLOMGREN Peter A.

  公开号：US20090082330A1

  公开（公告）日：2009-03-26

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  公式I的化合物能够抑制Btk，本文中对此进行了描述。描述了包含至少一个公式I化合物的药物组合物，以及至少一个从载体、佐剂和辅料中选择的药用辅料。描述了治疗患有对Btk活性抑制和/或B细胞活性有反应的某些疾病患者的方法。还描述了用于确定样本中存在Btk的方法。
• Benzenesulfonyl-Asymmetric Ureas and Medical Uses Thereof
  申请人：HELSINN HEALTHCARE SA

  公开号：US20170275301A1

  公开（公告）日：2017-09-28

  Benzenesulfonyl-asymmetric ureas are provided for the treatment of conditions modulated by the ghrelin receptor.

  苯磺酰基-不对称尿素用于治疗受胃饥饿素受体调节的疾病。
• HCV PROTEASE INHIBITORS
  申请人：Liu Chen-Fu

  公开号：US20110065737A1

  公开（公告）日：2011-03-17

  This invention relates to macrocyclic compounds of formula (I) shown in the specification. These compounds can be used to treat hepatitis C virus infection.

  本发明涉及规范中显示的式(I)的大环化合物。这些化合物可用于治疗丙型肝炎病毒感染。
• Certain Substituted Amides, Method of Making, and Method of Use Thereof
  申请人：Blomgren Peter A.

  公开号：US20110059944A1

  公开（公告）日：2011-03-10

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了抑制Btk的化合物I的配方。本文还描述了包括至少一种化合物I的制药组合物，以及至少一种从载体、佐剂和赋形剂中选择的药用可接受载体。本文还描述了治疗对抑制Btk活性和/或B细胞活性敏感的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。
• PYRIDAZINONES, METHOD OF MAKING, AND METHOD OF USE THEREOF
  申请人：Barbosa JR. Antonio J.M.

  公开号：US20110301145A1

  公开（公告）日：2011-12-08

  Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

  本文描述了化学式I的化合物，其能够抑制Btk。本文还描述了包含至少一种化学式I化合物的制药组合物，以及至少选择自载体、佐剂和赋形剂中的一种药学可接受载体的制药组合物。本文还描述了治疗对Btk活性和/或B细胞活性抑制有响应的某些疾病的患者的方法。本文还描述了检测样品中Btk存在的方法。